绝经后妇女子宫内膜取样示增殖期内膜的长期结局
这项回顾性队列研究纳入1997年1月至2008年12月间接受子宫内膜取样的1808名55岁及以上妇女,比较增殖期内膜与萎缩性内膜者日后发生子宫内膜增生或癌的风险。增殖期内膜组278例、萎缩性内膜组684例,前者发生子宫内膜增生或癌的风险为11.9% vs 2.9%(P<.0001),作者认为对绝经后出血且组织学为增殖期内膜的妇女应进行长期监测。
要点
- 绝经后妇女子宫内膜取样中约六分之一诊断为增殖期内膜。
- 增殖期内膜组发生子宫内膜增生或癌的风险为11.9% vs 萎缩性内膜组2.9%(P<.0001)。
- 增殖期内膜、年龄>60岁、BMI>35 kg/m2是进展为癌的显著危险因素。
核心结论
- 接受子宫内膜取样的绝经后妇女中,六分之一诊断为增殖期内膜。
- 增殖期内膜组11.9%发生子宫内膜增生或癌,发生率约为萎缩性内膜组的4倍。
- 作者认为对绝经后出血且组织学为增殖期内膜的妇女应进行长期监测。
- 作者提出需进一步研究是否需要治疗以消除无对抗雌激素的风险。
研究设计与样本
- 回顾性队列研究,纳入1997年1月至2008年12月间接受子宫内膜取样的1808名55岁及以上妇女,结局数据截至2018年2月。
- 962名妇女符合纳入标准,其中278例为增殖期内膜,684例为萎缩性内膜。
- 对绝经后出血者进行亚组分析,采用单因素和多因素logistic回归分析评估混杂因素。
主要发现
- 297名妇女(16.4%)诊断为增殖期内膜。
- 增殖期内膜组较萎缩性内膜组年轻(61.2 vs 64.5岁;P<.0001),体重指数更高(33.9 vs 30.6 kg/m2;P<.0001)。
- 增殖期内膜组发生子宫内膜增生或癌的风险为11.9% vs 萎缩性内膜组2.9%(P<.0001)。
- 增殖期内膜组任何子宫内膜癌为5.8% vs 1.8%(P=.002),非典型子宫内膜增生为2.2% vs 0.4%(P=.02),非非典型子宫内膜增生为2.0% vs 0.7%(P=.001)。
- 排除激素替代治疗病例后,发生子宫内膜癌和增生的风险仍相似(12.2% vs 3%;P=.001)。
关键数值与推荐
- 增殖期内膜组织学进展为癌的比值比3.89(95%置信区间2.03-7.49;P<.0001)。
- 年龄>60岁进展为癌的比值比1.98(95%置信区间1.03-3.82;P=.04)。
- 体重指数>35 kg/m2进展为癌的比值比2.3(95%置信区间1.09-4.83;P<.0001)。
临床怎么用
- 作者认为对绝经后出血且组织学为增殖期内膜的妇女应进行长期监测。
- 作者提出需进一步研究是否需要治疗以消除无对抗雌激素的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proliferative endometrium has been reported in 15% of endometrial biopsies of women aged 50 years and older. Contrary to endometrial hyperplasia, proliferative endometrium has not been associated with the risk of endometrial cancer. OBJECTIVE: This study aimed to report on the long-term outcome of postmenopausal women who received a diagnosis of proliferative endometrium. STUDY DESIGN: This is a retrospective cohort study of 1808 women aged 55 years and older who underwent endometrial sampling between January 1997 and December 2008. Outcome data were available through February 2018. Women with a proliferative endometrium were compared with those with an atrophic endometrium for future development of endometrial hyperplasia or cancer. A subanalysis was performed for those who presented with postmenopausal bleeding. Uni- and multivariable logistic regression analyses were used to assess for confounders. RESULTS: In this study, 297 women (16.4%) received a diagnosis of proliferative endometrium. Furthermore, 962 women met the inclusion criteria. Among those women, 278 had a proliferative endometrium, and 684 had an atrophic endometrium. Women with a proliferative endometrium were younger (61.2 vs 64.5 years; P<.0001) and had a higher body mass index (33.9 vs 30.6 kg/m2; P<.0001). More African American women had a proliferative endometrium. Both groups had a similar length of surveillance (11.9 vs 11.5 years; P=.27). Women with a proliferative endometrium had a higher risk of developing endometrial hyperplasia or cancer (11.9% vs 2.9%; P<.0001), any endometrial cancer (5.8% vs 1.8%; P=.002), atypical endometrial hyperplasia (2.2% vs 0.4%; P=.02), and nonatypical endometrial hyperplasia (2.0% vs 0.7%; P=.001). The risk of developing endometrial cancer and endometrial hyperplasia remained similar after excluding cases on hormonal replacement therapy (12.2% vs 3%; P=.001). On logistic regression analysis, proliferative endometrium histology (odds ratio, 3.89; 95% confidence interval, 2.03-7.49; P<.0001), age >60 years (odds ratio, 1.98; 95% confidence interval, 1.03-3.82; P=.04), and body mass index >35 kg/m2 (odds ratio, 2.3; 95% confidence interval, 1.09-4.83; P<.0001) remained significant risk factors for progression to cancer. CONCLUSION: One of the 6 postmenopausal women who underwent endometrial sampling had a proliferative endometrium. Furthermore, 11.9% of women developed endometrial hyperplasia or cancer, a 4-fold greater incidence than women with an atrophic endometrium. The findings of this study suggest that long-term monitoring is warranted for women with postmenopausal bleeding and a proliferative endometrium histology. Further studies are needed to examine if a treatment is required to negate the risk of unopposed estrogen.
引用
- Rotenberg O, Doulaveris G, Fridman D, et al. Long-term outcome of postmenopausal women with proliferative endometrium on endometrial sampling. Am J Obstet Gynecol. 2020. PMID: 32640199. doi:10.1016/j.ajog.2020.06.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。